Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome

Gandara, David R.; Leigh, Bryan R.; Vallières, Eric; Albain, Kathy S.

doi:10.1016/s0169-5002(99)00056-2

Cited by 9 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second aim is systemic tumor control, achieved by systemic therapy. Some data, based on a small number of patients, hypothesize that complete remission in mediastinal lymph node metastases is predictive for systemic tumor control [4] [19].…”

Section: Goals Of Therapymentioning

confidence: 99%

Is <sup>18</sup>F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?

Klass¹,

Baüm²,

Schmuecking³

et al. 2014

JCT

View full text Add to dashboard Cite

show abstract

Section: Goals Of Therapymentioning

confidence: 99%

Is <sup>18</sup>F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?

Klass¹,

Baüm²,

Schmuecking³

et al. 2014

JCT

View full text Add to dashboard Cite

show abstract

“…Both of these trials demonstrated a benefit for preoperative chemotherapy with hazard ratios for survival improving five-to sevenfold compared to surgery alone. Unfortunately, the total patient sample size in each trial was small and so the general applicability of these regimens in the day-to-day treatment of patients is still in doubt [98]. In a consensus report, GANDARA et al [98] write the following about induction chemotherapy: "While preoperative chemotherapy cannot be considered standard of care, it does appear to be a reasonable strategy in minimal stage III-a disease, assuming the multimodality team involved is experienced in this approach and works in a collaborative fashion to maximize efficacy and minimize potential toxicities.…”

Section: Surgical Management Of N2 Lung Cancermentioning

confidence: 99%

Current surgical treatment of nonsmall cell lung cancer 2001

Deslauriers¹

2002

Eur Respir J

View full text Add to dashboard Cite

Recognizing that surgical treatment is still the best option for controlling lung cancer, surgeons want an operation to be performed when the benefits clearly outweigh the possible risks, and when it has been determined that cancer resection is the most appropriate course of management. The necessity for a compulsive attitude toward preoperative assessment is therefore to be emphasized.Approximately 45% of all lung cancers are limited to the chest, where surgical resection is the most effective method of controlling the disease. Patients with tumour (T) 1, node (N) 0 and T2N0 tumours have early lung cancer, and most are curable by resection, with 5-yr survival rates in the range 75-80% for patients with T1N0 status. The "gold standard" of surgery remains lobectomy. Stage T1N1 and T2N1 carcinomas represent a group of patients in whom the disease involves hilar and bronchopulmonary nodes. This group is best treated by complete resection and mediastinal lymphadenectomy.Survival data following surgical resection of T3 tumours clearly show better survival in patients with T3N0 disease than in those with T3N1-2 disease. Five-year survival rates for completely resected T3N0 lesions are in the range 30-50%. Once N1 disease is present, survival decreases to 15-20%. Incomplete resections fail to cure and surgery is not indicated if N2 disease is documented preoperatively. On occasion, T4 tumours involving the carina or vertebral body can be completely resected but T4N1-2 lesions are virtually incurable by surgery.The presence of mediastinal lymph node metastasis (N2/N3 disease) is an ominous prognostic sign and stage III-b disease, by virtue of metastatic contralateral nodes, is an absolute contraindication to surgical resection. Induction treatments with chemoradiation have shown prolongation of survival and three randomized trials have demonstrated a survival advantage over surgery alone.

show abstract

“…der Induktions-Chemo-Radiotherapie vor chirurgischer Resektion nicht-kleinzelliger Lungencarcinome des Stadiums III wird immer noch kontrovers betrachtet [3,20,21,24]. der Induktions-Chemo-Radiotherapie vor chirurgischer Resektion nicht-kleinzelliger Lungencarcinome des Stadiums III wird immer noch kontrovers betrachtet [3,20,21,24].…”

Section: Induktions-chemo-radiotherapie ± Phase-ii-studienunclassified

“…der Induktions-Chemo-Radiotherapie vor chirurgischer Resektion nicht-kleinzelliger Lungencarcinome des Stadiums III wird immer noch kontrovers betrachtet [3,20,21,24]. Vorläufige Pilotstudien sprechen für eine Überlegenheit der Positronenemissionstomographie gegenüber der Computertomographie in dieser Situation [24]. Eine kritische Interpretation der bisher vorliegenden Ergebnisse muss verschiedene Aspekte berücksichtigen [ [63].…”

Section: Induktions-chemo-radiotherapie ± Phase-ii-studienunclassified

“…Eine kritische Interpretation der bisher vorliegenden Ergebnisse muss verschiedene Aspekte berücksichtigen [ [63]. Einige Kliniker fordern diesen multimodalen Ansatz bereits bei der Mehrheit ihrer Patienten im Stadium III [24]. In dieser Studie galten alle Patienten, bei denen es unter einer Induktions-Chemotherapie nicht zu einer Tumorprogression gekommen ist, als geeignet für die chirurgische Resektion.…”

Section: Induktions-chemo-radiotherapie ± Phase-ii-studienunclassified

See 1 more Smart Citation

Differentialindikation zur Induktionstherapie bei nicht-kleinzelligen Lungentumoren

Drings¹,

Manegold²

2000

Chirurg

View full text Add to dashboard Cite

Induction chemotherapy and induction chemo-radiotherapy have shown their efficiency and feasibility in many phase-II studies and have profen superior to operation alone in stage IIIa of NSCLC in several phase-III studies. Therefore it is justified to recommend this multimodal therapy in stage IIIa N2 disease within clinical studies. However, it is currently not justified to present this multimodal treatment modality as a generally agreed standard.

show abstract

Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome

Cited by 9 publications

References 12 publications

Is <sup>18</sup>F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?

Is <sup>18</sup>F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?

Current surgical treatment of nonsmall cell lung cancer 2001

Differentialindikation zur Induktionstherapie bei nicht-kleinzelligen Lungentumoren

Contact Info

Product

Resources

About

Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome

Cited by 9 publications

References 12 publications

Is &lt;sup&gt;18&lt;/sup&gt;F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?

Is &lt;sup&gt;18&lt;/sup&gt;F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?

Current surgical treatment of nonsmall cell lung cancer 2001

Differentialindikation zur Induktionstherapie bei nicht-kleinzelligen Lungentumoren

Contact Info

Product

Resources

About

Is <sup>18</sup>F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?

Is <sup>18</sup>F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?